MTOR and tuberous sclerosis: The study identified amongst 11 dermatological conditions that over 157 of the 262 patients frequently had mostly angiofibromas linked to TSC, and that topically applied mTOR inhibitors, such as sirolimus was more effective against angiofibromas than placebo and were well tolerated [197].